Recent advances in immunotherapy have affirmed the curative potential of T cell-based
approaches for treating relapsed and refractory cancers. However, the therapeutic efficacy is …

Chimeric antigen receptor (CAR) T cell therapy, which targets tumors with high specificity
through the recognition of particular antigens, has emerged as one of the most rapidly …

Enormous patients with gastric cancer (GC) are insensitive to chemotherapy and targeted
therapy without the chance of radical surgery, so immunotherapy may supply a novel choice …

Chimeric antigen receptor (CAR) T cell therapies have transformed outcomes for many
patients with hematological malignancies. However, some patients do not respond to CAR T …

Targeting systemic IL-2 to BCMA CAR-T cells | Nature Immunology Skip to main content Thank
you for visiting nature.com. You are using a browser version with limited support for CSS. To …

Chimeric antigen receptor (CAR) T cell therapies have transformed outcomes for many
patients with hematological malignancies. However, some patients do not respond to CAR T …

Purpose: Clinical efficacy of chimeric antigen receptor (CAR) T cells against pediatric
osteosarcoma (OS) has been limited. One strategy to improve efficacy may be to drive …

The immunosuppressive tumor microenvironment represents a key challenge for chimeric
antigen receptor (CAR) T cells in solid tumors and includes the production of the inhibitory …

Ovarian cancer (OC) is a common gynecological tumor with high mortality, which is difficult
to control its progression with conventional treatments and is prone to recurrence. Recent …

Background Oncofetal splice variants of extracellular matrix (ECM) proteins present a
unique group of target antigens for the immunotherapy of pediatric cancers. However …